---
authors:
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
    familyNames:
      - Trilla-Fuertes
    givenNames:
      - Lucía
  - type: Person
    affiliations:
      - type: Organization
        name: 'Urology Service, Hospital Universitario 12 de Octubre, Madrid, Spain'
    familyNames:
      - Miranda
    givenNames:
      - Natalia
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Medical Oncology Service, Hospital Universitario 12 de Octubre,
          Madrid, Spain
    familyNames:
      - Castellano
    givenNames:
      - Daniel
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Molecular Oncology and Pathology Lab, Hospital Universitario La
          Paz-IdiPAZ, Madrid, Spain
    familyNames:
      - López-Vacas
    givenNames:
      - Rocío
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Medical Oncology Service, Hospital Universitario 12 de Octubre,
          Madrid, Spain
      - type: Organization
        name: 'Clínica Internacional S.A., Lima, Perú'
    familyNames:
      - Farfán
      - Tello
    givenNames:
      - Carlos
      - A.
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Medical Oncology Service, Hospital Universitario 12 de Octubre,
          Madrid, Spain
    familyNames:
      - de
      - Velasco
    givenNames:
      - Guillermo
  - type: Person
    affiliations:
      - type: Organization
        name: 'Urology Department, Clínica Universidad de Navarra, Madrid, Spain'
    familyNames:
      - Villacampa
    givenNames:
      - Felipe
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
    familyNames:
      - López-Camacho
    givenNames:
      - Elena
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
      - type: Organization
        name: >-
          Molecular Oncology and Pathology Lab, Hospital Universitario La
          Paz-IdiPAZ, Madrid, Spain
    familyNames:
      - Prado-Vázquez
    givenNames:
      - Guillermo
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
      - type: Organization
        name: >-
          Molecular Oncology and Pathology Lab, Hospital Universitario La
          Paz-IdiPAZ, Madrid, Spain
      - type: Organization
        name: >-
          Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII,
          Madrid, Spain
    familyNames:
      - Zapater-Moros
    givenNames:
      - Andrea
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII,
          Madrid, Spain
      - type: Organization
        name: >-
          Medical Oncology Service, La Paz University Hospital-IdiPAZ, Madrid,
          Spain
    familyNames:
      - Espinosa
    givenNames:
      - Enrique
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
      - type: Organization
        name: >-
          Molecular Oncology and Pathology Lab, Hospital Universitario La
          Paz-IdiPAZ, Madrid, Spain
      - type: Organization
        name: >-
          Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII,
          Madrid, Spain
    familyNames:
      - Fresno
      - Vara
    givenNames:
      - Juan
      - Ángel
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Medical Oncology Service, La Paz University Hospital-IdiPAZ, Madrid,
          Spain
    familyNames:
      - Pinto
    givenNames:
      - Álvaro
  - type: Person
    affiliations:
      - type: Organization
        name: 'Biomedica Molecular Medicine SL, Madrid, Spain'
      - type: Organization
        name: >-
          Molecular Oncology and Pathology Lab, Hospital Universitario La
          Paz-IdiPAZ, Madrid, Spain
    familyNames:
      - Gámez-Pozo
    givenNames:
      - Angelo
dateAccepted:
  type: Date
  value: '2020-01-28'
datePublished:
  type: Date
  value: '2020-02-28'
dateReceived:
  type: Date
  value: '2019-12-05'
description:
  - type: Paragraph
    content:
      - >-
        Renal cell carcinoma comprises a variety of entities, the most common
        being the clear-cell, papillary and chromophobe subtypes. These subtypes
        are related to different clinical evolution; however, most therapies
        have been developed for clear-cell carcinoma and there is not a specific
        treatment based on different subtypes. In this study, one hundred and
        sixty-four paraffin samples from primary nephrectomies for localized
        tumors were analyzed. MiRNAs were isolated and measured by microRNA
        arrays. Significance Analysis of Microarrays and Consensus Cluster
        algorithm were used to characterize different renal subtypes. The
        analyses showed that chromophobe renal tumors are a homogeneous group
        characterized by an overexpression of miR 1229, miR 10a, miR 182, miR
        1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the
        other hand, clear cell renal carcinomas presented two different groups
        inside this histological subtype, with differences in miRNAs that
        regulate focal adhesion, transcription, apoptosis and angiogenesis
        processes. Specifically, one of the defined groups had an overexpression
        of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion,
        differences in miRNA expression profiles between histological renal
        subtypes were established. In addition, clear cell renal carcinomas had
        different expression of proangiogenic miRNAs. With the emergence of
        antiangiogenic drugs, these differences could be used as therapeutic
        targets in the future or as a selection method for tailoring
        personalized treatments.
editors:
  - type: Person
    affiliations:
      - type: Organization
        name: 'Universitat des Saarlandes, GERMANY'
    familyNames:
      - Roemer
    givenNames:
      - Klaus
fundedBy:
  - type: MonetaryGrant
    funders:
      - type: Organization
        name: Instituto de Salud Carlos III
    identifiers:
      - type: PropertyValue
        value: PI07/1302
  - type: MonetaryGrant
    funders:
      - type: Organization
        name: Ministerio de Economía y Competitividad (ES)
    identifiers:
      - type: PropertyValue
        value: DI-15-07614
  - type: MonetaryGrant
    funders:
      - type: Organization
        name: Ministerio de Economía y Competitividad (ES)
    identifiers:
      - type: PropertyValue
        value: PTQ2018-009760
  - type: MonetaryGrant
    funders:
      - type: Organization
        name: 'Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (ES)'
    identifiers:
      - type: PropertyValue
        value: IND2017/BMD7783
  - type: MonetaryGrant
    funders:
      - type: Organization
        name: 'Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (ES)'
    identifiers:
      - type: PropertyValue
        value: IND2018/BMD-9262
identifiers:
  - type: PropertyValue
    name: doi
    propertyID: 'https://registry.identifiers.org/registry/doi'
    value: 10.1371/journal.pone.0229075
  - type: PropertyValue
    name: publisher-id
    propertyID: 'https://registry.identifiers.org/registry/publisher-id'
    value: PONE-D-19-33682
  - type: PropertyValue
    name: elocation-id
    propertyID: 'https://registry.identifiers.org/registry/elocation-id'
    value: e0229075
isPartOf:
  type: PublicationVolume
  isPartOf:
    type: Periodical
    identifiers:
      - type: PropertyValue
        name: nlm-ta
        propertyID: 'https://registry.identifiers.org/registry/nlm-ta'
        value: PLoS ONE
      - type: PropertyValue
        name: publisher-id
        propertyID: 'https://registry.identifiers.org/registry/publisher-id'
        value: plos
      - type: PropertyValue
        name: pmc
        propertyID: 'https://registry.identifiers.org/registry/pmc'
        value: plosone
    issns:
      - 1932-6203
    publisher:
      type: Organization
      name: Public Library of Science
    title: PLOS ONE
  volumeNumber: '15'
licenses:
  - type: CreativeWork
    url: 'http://creativecommons.org/licenses/by/4.0/'
    content:
      - type: Paragraph
        content:
          - 'This is an open access article distributed under the terms of the '
          - type: Link
            target: 'http://creativecommons.org/licenses/by/4.0/'
            content:
              - Creative Commons Attribution License
          - >-
            , which permits unrestricted use, distribution, and reproduction in
            any medium, provided the original author and source are credited.
references:
  - type: Article
    id: pone-0229075-ref001
    authors:
      - type: Person
        familyNames:
          - Siegel
        givenNames:
          - RL
      - type: Person
        familyNames:
          - Miller
        givenNames:
          - KD
      - type: Person
        familyNames:
          - Jemal
        givenNames:
          - A
    datePublished: '2019'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: CA Cancer J Clin
        volumeNumber: 69
      issueNumber: 1
    pageEnd: 34
    pageStart: 7
    title: 'Cancer statistics, 2019'
  - type: Article
    id: pone-0229075-ref002
    authors:
      - type: Person
        familyNames:
          - Janzen
        givenNames:
          - NK
      - type: Person
        familyNames:
          - Kim
        givenNames:
          - HL
      - type: Person
        familyNames:
          - Figlin
        givenNames:
          - RA
      - type: Person
        familyNames:
          - Belldegrun
        givenNames:
          - AS
    datePublished: '2003'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Urol Clin North Am
        volumeNumber: 30
      issueNumber: 4
    pageEnd: 52
    pageStart: 843
    title: >-
      Surveillance after radical or partial nephrectomy for localized renal cell
      carcinoma and management of recurrent disease
  - type: Article
    id: pone-0229075-ref003
    authors:
      - type: Person
        familyNames:
          - Janowitz
        givenNames:
          - T
      - type: Person
        familyNames:
          - Welsh
        givenNames:
          - SJ
      - type: Person
        familyNames:
          - Zaki
        givenNames:
          - K
      - type: Person
        familyNames:
          - Mulders
        givenNames:
          - P
      - type: Person
        familyNames:
          - Eisen
        givenNames:
          - T
    datePublished: '2013'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Semin Oncol
        volumeNumber: 40
      issueNumber: 4
    pageEnd: 91
    pageStart: 482
    title: 'Adjuvant therapy in renal cell carcinoma-past, present, and future'
  - type: Article
    id: pone-0229075-ref004
    authors:
      - type: Person
        familyNames:
          - Staehler
        givenNames:
          - M
      - type: Person
        familyNames:
          - Motzer
        givenNames:
          - RJ
      - type: Person
        familyNames:
          - George
        givenNames:
          - DJ
      - type: Person
        familyNames:
          - Pandha
        givenNames:
          - HS
      - type: Person
        familyNames:
          - Donskov
        givenNames:
          - F
      - type: Person
        familyNames:
          - Escudier
        givenNames:
          - B
    datePublished: '2018'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Ann Oncol
        volumeNumber: 29
      issueNumber: 10
    pageEnd: 104
    pageStart: 2098
    title: >-
      Adjuvant sunitinib in patients with high-risk renal cell carcinoma:
      safety, therapy management, and patient-reported outcomes in the S-TRAC
      trial
  - type: Article
    id: pone-0229075-ref005
    authors:
      - type: Person
        familyNames:
          - Lawrence
        givenNames:
          - NJ
      - type: Person
        familyNames:
          - Martin
        givenNames:
          - A
      - type: Person
        familyNames:
          - Davis
        givenNames:
          - ID
      - type: Person
        familyNames:
          - Troon
        givenNames:
          - S
      - type: Person
        familyNames:
          - Sengupta
        givenNames:
          - S
      - type: Person
        familyNames:
          - Hovey
        givenNames:
          - E
    datePublished: '2018'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Kidney Cancer
        volumeNumber: 2
      issueNumber: 2
    pageEnd: 31
    pageStart: 123
    title: >-
      What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile
      After Resection of Intermediate- or High-Risk Renal Cell Carcinoma?
      Clinical Investigators' Preferences in the SORCE Trial
  - type: Article
    id: pone-0229075-ref006
    authors:
      - type: Person
        familyNames:
          - Motzer
        givenNames:
          - RJ
      - type: Person
        familyNames:
          - Haas
        givenNames:
          - NB
      - type: Person
        familyNames:
          - Donskov
        givenNames:
          - F
      - type: Person
        familyNames:
          - Gross-Goupil
        givenNames:
          - M
      - type: Person
        familyNames:
          - Varlamov
        givenNames:
          - S
      - type: Person
        familyNames:
          - Kopyltsov
        givenNames:
          - E
    datePublished: '2017'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: J Clin Oncol
        volumeNumber: 35
      issueNumber: 35
    pageEnd: 23
    pageStart: 3916
    title: >-
      Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After
      Nephrectomy in Patients With Localized or Locally Advanced Renal Cell
      Carcinoma
  - type: Article
    id: pone-0229075-ref007
    authors:
      - type: Person
        familyNames:
          - Gross-Goupil
        givenNames:
          - M
      - type: Person
        familyNames:
          - Kwon
        givenNames:
          - TG
      - type: Person
        familyNames:
          - Eto
        givenNames:
          - M
      - type: Person
        familyNames:
          - Ye
        givenNames:
          - D
      - type: Person
        familyNames:
          - Miyake
        givenNames:
          - H
      - type: Person
        familyNames:
          - Seo
        givenNames:
          - SI
    datePublished: '2018'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Ann Oncol
        volumeNumber: 29
      issueNumber: 12
    pageEnd: 8
    pageStart: 2371
    title: >-
      Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma:
      results from the phase III, randomized ATLAS trial
  - type: Article
    id: pone-0229075-ref008
    authors:
      - type: Person
        familyNames:
          - Moch
        givenNames:
          - H
      - type: Person
        familyNames:
          - Cubilla
        givenNames:
          - AL
      - type: Person
        familyNames:
          - Humphrey
        givenNames:
          - PA
      - type: Person
        familyNames:
          - Reuter
        givenNames:
          - VE
      - type: Person
        familyNames:
          - Ulbright
        givenNames:
          - TM
    datePublished: '2016'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Eur Urol
        volumeNumber: 70
      issueNumber: 1
    pageEnd: 105
    pageStart: 93
    title: >-
      The 2016 WHO Classification of Tumours of the Urinary System and Male
      Genital Organs-Part A: Renal, Penile, and Testicular Tumours
  - type: Article
    id: pone-0229075-ref009
    authors:
      - type: Person
        familyNames:
          - Ricketts
        givenNames:
          - CJ
      - type: Person
        familyNames:
          - De
          - Cubas
        givenNames:
          - AA
      - type: Person
        familyNames:
          - Fan
        givenNames:
          - H
      - type: Person
        familyNames:
          - Smith
        givenNames:
          - CC
      - type: Person
        familyNames:
          - Lang
        givenNames:
          - M
      - type: Person
        familyNames:
          - Reznik
        givenNames:
          - E
    datePublished: '2018'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Cell Rep
        volumeNumber: 23
      issueNumber: 1
    title: >-
      The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal
      Cell Carcinoma
  - type: Article
    id: pone-0229075-ref010
    authors:
      - type: Person
        familyNames:
          - Linehan
        givenNames:
          - WM
      - type: Person
        familyNames:
          - Spellman
        givenNames:
          - PT
      - type: Person
        familyNames:
          - Ricketts
        givenNames:
          - CJ
      - type: Person
        familyNames:
          - Creighton
        givenNames:
          - CJ
      - type: Person
        familyNames:
          - Fei
        givenNames:
          - SS
      - type: Person
        familyNames:
          - Davis
        givenNames:
          - C
    datePublished: '2016'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: N Engl J Med
        volumeNumber: 374
      issueNumber: 2
    pageEnd: 45
    pageStart: 135
    title: Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
  - type: Article
    id: pone-0229075-ref011
    authors:
      - type: Person
        familyNames:
          - Wang
        givenNames:
          - WT
      - type: Person
        familyNames:
          - Chen
        givenNames:
          - YQ
    datePublished: '2014'
    isPartOf:
      type: PublicationVolume
      isPartOf:
        type: Periodical
        name: J Hematol Oncol
      volumeNumber: 7
    pageStart: 86
    title: 'Circulating miRNAs in cancer: from detection to therapy'
  - type: Article
    id: pone-0229075-ref012
    authors:
      - type: Person
        familyNames:
          - Kakimoto
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Tanaka
        givenNames:
          - M
      - type: Person
        familyNames:
          - Kamiguchi
        givenNames:
          - H
      - type: Person
        familyNames:
          - Ochiai
        givenNames:
          - E
      - type: Person
        familyNames:
          - Osawa
        givenNames:
          - M
    datePublished: '2016'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: PLoS One
        volumeNumber: 11
      issueNumber: 9
    title: 'MicroRNA Stability in FFPE Tissue Samples: Dependence on GC Content'
  - type: Article
    id: pone-0229075-ref013
    authors:
      - type: Person
        familyNames:
          - Si
        givenNames:
          - W
      - type: Person
        familyNames:
          - Shen
        givenNames:
          - J
      - type: Person
        familyNames:
          - Zheng
        givenNames:
          - H
      - type: Person
        familyNames:
          - Fan
        givenNames:
          - W
    datePublished: '2019'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Clin Epigenetics
        volumeNumber: 11
      issueNumber: 1
    pageStart: 25
    title: The role and mechanisms of action of microRNAs in cancer drug resistance
  - type: Article
    id: pone-0229075-ref014
    authors:
      - type: Person
        familyNames:
          - Lee
        givenNames:
          - YS
      - type: Person
        familyNames:
          - Dutta
        givenNames:
          - A
    datePublished: '2009'
    isPartOf:
      type: PublicationVolume
      isPartOf:
        type: Periodical
        name: Annu Rev Pathol
      volumeNumber: 4
    pageEnd: 227
    pageStart: 199
    title: MicroRNAs in cancer
  - type: Article
    id: pone-0229075-ref015
    authors:
      - type: Person
        familyNames:
          - Gámez-Pozo
        givenNames:
          - A
      - type: Person
        familyNames:
          - Berges-Soria
        givenNames:
          - J
      - type: Person
        familyNames:
          - Arevalillo
        givenNames:
          - JM
      - type: Person
        familyNames:
          - Nanni
        givenNames:
          - P
      - type: Person
        familyNames:
          - López-Vacas
        givenNames:
          - R
      - type: Person
        familyNames:
          - Navarro
        givenNames:
          - H
    datePublished: '2015'
    isPartOf:
      type: Periodical
      name: Cancer Res
    pageEnd: 53
    pageStart: 2243
    title: >-
      Combined label-free quantitative proteomics and microRNA expression
      analysis of breast cancer unravel molecular differences with clinical
      implications
  - type: Article
    id: pone-0229075-ref016
    authors:
      - type: Person
        familyNames:
          - Gámez-Pozo
        givenNames:
          - A
      - type: Person
        familyNames:
          - Antón-Aparicio
        givenNames:
          - LM
      - type: Person
        familyNames:
          - Bayona
        givenNames:
          - C
      - type: Person
        familyNames:
          - Borrega
        givenNames:
          - P
      - type: Person
        familyNames:
          - Gallegos
          - Sancho
        givenNames:
          - MI
      - type: Person
        familyNames:
          - García-Domínguez
        givenNames:
          - R
    datePublished: '2012'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Neoplasia
        volumeNumber: 14
      issueNumber: 12
    pageEnd: 52
    pageStart: 1144
    title: >-
      MicroRNA expression profiling of peripheral blood samples predicts
      resistance to first-line sunitinib in advanced renal cell carcinoma
      patients
  - type: Article
    id: pone-0229075-ref017
    authors:
      - type: Person
        familyNames:
          - López-Romero
        givenNames:
          - P
      - type: Person
        familyNames:
          - González
        givenNames:
          - MA
      - type: Person
        familyNames:
          - Callejas
        givenNames:
          - S
      - type: Person
        familyNames:
          - Dopazo
        givenNames:
          - A
      - type: Person
        familyNames:
          - Irizarry
        givenNames:
          - RA
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      isPartOf:
        type: Periodical
        name: BMC Res Notes
      volumeNumber: 3
    pageStart: 18
    title: Processing of Agilent microRNA array data
  - type: Article
    id: pone-0229075-ref018
    authors:
      - type: Person
        familyNames:
          - Johnson
        givenNames:
          - WE
      - type: Person
        familyNames:
          - Li
        givenNames:
          - C
      - type: Person
        familyNames:
          - Rabinovic
        givenNames:
          - A
    datePublished: '2007'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Biostatistics
        volumeNumber: 8
      issueNumber: 1
    pageEnd: 27
    pageStart: 118
    title: >-
      Adjusting batch effects in microarray expression data using empirical
      Bayes methods
  - type: Article
    id: pone-0229075-ref019
    authors:
      - type: Person
        familyNames:
          - Monti
        givenNames:
          - S
      - type: Person
        familyNames:
          - Tamayo
        givenNames:
          - P
      - type: Person
        familyNames:
          - Mesirov
        givenNames:
          - J
      - type: Person
        familyNames:
          - Golub
        givenNames:
          - T
    datePublished: '2003'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Machine learning
        volumeNumber: 52
      issueNumber: 1
    pageEnd: 118
    pageStart: 91
    title: >-
      Consensus Clustering: A Resampling-Based Method for Class Discovery and
      Visualization of Gene Expression Microarray Data
  - type: Article
    id: pone-0229075-ref020
    authors:
      - type: Person
        familyNames:
          - Saeed
        givenNames:
          - AI
      - type: Person
        familyNames:
          - Sharov
        givenNames:
          - V
      - type: Person
        familyNames:
          - White
        givenNames:
          - J
      - type: Person
        familyNames:
          - Li
        givenNames:
          - J
      - type: Person
        familyNames:
          - Liang
        givenNames:
          - W
      - type: Person
        familyNames:
          - Bhagabati
        givenNames:
          - 'N'
    datePublished: '2003'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Biotechniques
        volumeNumber: 34
      issueNumber: 2
    pageEnd: 8
    pageStart: 374
    title: >-
      TM4: a free, open-source system for microarray data management and
      analysis
  - type: Article
    id: pone-0229075-ref021
    authors:
      - type: Person
        familyNames:
          - Tusher
        givenNames:
          - VG
      - type: Person
        familyNames:
          - Tibshirani
        givenNames:
          - R
      - type: Person
        familyNames:
          - Chu
        givenNames:
          - G
    datePublished: '2001'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Proc Natl Acad Sci U S A
        volumeNumber: 98
      issueNumber: 9
    pageEnd: 21
    pageStart: 5116
    title: >-
      Significance analysis of microarrays applied to the ionizing radiation
      response
  - type: Article
    id: pone-0229075-ref022
    authors:
      - type: Person
        familyNames:
          - Dweep
        givenNames:
          - H
      - type: Person
        familyNames:
          - Sticht
        givenNames:
          - C
      - type: Person
        familyNames:
          - Pandey
        givenNames:
          - P
      - type: Person
        familyNames:
          - Gretz
        givenNames:
          - 'N'
    datePublished: '2011'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: J Biomed Inform
        volumeNumber: 44
      issueNumber: 5
    pageEnd: 47
    pageStart: 839
    title: >-
      miRWalk—database: prediction of possible miRNA binding sites by "walking"
      the genes of three genomes
  - type: Article
    id: pone-0229075-ref023
    authors:
      - type: Person
        familyNames:
          - Chen
        givenNames:
          - EY
      - type: Person
        familyNames:
          - Tan
        givenNames:
          - CM
      - type: Person
        familyNames:
          - Kou
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Duan
        givenNames:
          - Q
      - type: Person
        familyNames:
          - Wang
        givenNames:
          - Z
      - type: Person
        familyNames:
          - Meirelles
        givenNames:
          - GV
    datePublished: '2013'
    isPartOf:
      type: PublicationVolume
      isPartOf:
        type: Periodical
        name: BMC Bioinformatics
      volumeNumber: 14
    pageStart: 128
    title: >-
      Enrichr: interactive and collaborative HTML5 gene list enrichment analysis
      tool
  - type: Article
    id: pone-0229075-ref024
    authors:
      - type: Person
        familyNames:
          - Silva-Santos
        givenNames:
          - RM
      - type: Person
        familyNames:
          - Costa-Pinheiro
        givenNames:
          - P
      - type: Person
        familyNames:
          - Luis
        givenNames:
          - A
      - type: Person
        familyNames:
          - Antunes
        givenNames:
          - L
      - type: Person
        familyNames:
          - Lobo
        givenNames:
          - F
      - type: Person
        familyNames:
          - Oliveira
        givenNames:
          - J
    datePublished: '2013'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Br J Cancer
        volumeNumber: 109
      issueNumber: 10
    pageEnd: 53
    pageStart: 2646
    title: >-
      MicroRNA profile: a promising ancillary tool for accurate renal cell
      tumour diagnosis
  - type: Article
    id: pone-0229075-ref025
    authors:
      - type: Person
        familyNames:
          - Youssef
        givenNames:
          - YM
      - type: Person
        familyNames:
          - White
        givenNames:
          - NM
      - type: Person
        familyNames:
          - Grigull
        givenNames:
          - J
      - type: Person
        familyNames:
          - Krizova
        givenNames:
          - A
      - type: Person
        familyNames:
          - Samy
        givenNames:
          - C
      - type: Person
        familyNames:
          - Mejia-Guerrero
        givenNames:
          - S
    datePublished: '2011'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Eur Urol
        volumeNumber: 59
      issueNumber: 5
    pageEnd: 30
    pageStart: 721
    title: >-
      Accurate molecular classification of kidney cancer subtypes using microRNA
      signature
  - type: Article
    id: pone-0229075-ref026
    authors:
      - type: Person
        familyNames:
          - Powers
        givenNames:
          - MP
      - type: Person
        familyNames:
          - Alvarez
        givenNames:
          - K
      - type: Person
        familyNames:
          - Kim
        givenNames:
          - HJ
      - type: Person
        familyNames:
          - Monzon
        givenNames:
          - FA
    datePublished: '2011'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Diagn Mol Pathol
        volumeNumber: 20
      issueNumber: 2
    pageEnd: 70
    pageStart: 63
    title: >-
      Molecular classification of adult renal epithelial neoplasms using
      microRNA expression and virtual karyotyping
  - type: Article
    id: pone-0229075-ref027
    authors:
      - type: Person
        familyNames:
          - Ma
        givenNames:
          - X
      - type: Person
        familyNames:
          - Shen
        givenNames:
          - D
      - type: Person
        familyNames:
          - Li
        givenNames:
          - H
      - type: Person
        familyNames:
          - Zhang
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Lv
        givenNames:
          - X
      - type: Person
        familyNames:
          - Huang
        givenNames:
          - Q
    datePublished: '2015'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Urol Oncol
        volumeNumber: 33
      issueNumber: 4
    title: >-
      MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by
      targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal
      cell carcinoma
  - type: Article
    id: pone-0229075-ref028
    authors:
      - type: Person
        familyNames:
          - Yuan
        givenNames:
          - HX
      - type: Person
        familyNames:
          - Zhang
        givenNames:
          - JP
      - type: Person
        familyNames:
          - Kong
        givenNames:
          - WT
      - type: Person
        familyNames:
          - Liu
        givenNames:
          - YJ
      - type: Person
        familyNames:
          - Lin
        givenNames:
          - ZM
      - type: Person
        familyNames:
          - Wang
        givenNames:
          - WP
    datePublished: '2014'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Tumour Biol
        volumeNumber: 35
      issueNumber: 12
    pageEnd: 63
    pageStart: 12757
    title: >-
      Elevated microRNA-185 is associated with high vascular endothelial growth
      factor receptor 2 expression levels and high microvessel density in clear
      cell renal cell carcinoma
  - type: Article
    id: pone-0229075-ref029
    authors:
      - type: Person
        familyNames:
          - Harris
        givenNames:
          - TA
      - type: Person
        familyNames:
          - Yamakuchi
        givenNames:
          - M
      - type: Person
        familyNames:
          - Ferlito
        givenNames:
          - M
      - type: Person
        familyNames:
          - Mendell
        givenNames:
          - JT
      - type: Person
        familyNames:
          - Lowenstein
        givenNames:
          - CJ
    datePublished: '2008'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Proc Natl Acad Sci U S A
        volumeNumber: 105
      issueNumber: 5
    pageEnd: 21
    pageStart: 1516
    title: >-
      MicroRNA-126 regulates endothelial expression of vascular cell adhesion
      molecule 1
  - type: Article
    id: pone-0229075-ref030
    authors:
      - type: Person
        familyNames:
          - Fish
        givenNames:
          - JE
      - type: Person
        familyNames:
          - Santoro
        givenNames:
          - MM
      - type: Person
        familyNames:
          - Morton
        givenNames:
          - SU
      - type: Person
        familyNames:
          - Yu
        givenNames:
          - S
      - type: Person
        familyNames:
          - Yeh
        givenNames:
          - RF
      - type: Person
        familyNames:
          - Wythe
        givenNames:
          - JD
    datePublished: '2008'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Dev Cell
        volumeNumber: 15
      issueNumber: 2
    pageEnd: 84
    pageStart: 272
    title: miR-126 regulates angiogenic signaling and vascular integrity
  - type: Article
    id: pone-0229075-ref031
    authors:
      - type: Person
        familyNames:
          - Khella
        givenNames:
          - HW
      - type: Person
        familyNames:
          - Scorilas
        givenNames:
          - A
      - type: Person
        familyNames:
          - Mozes
        givenNames:
          - R
      - type: Person
        familyNames:
          - Mirham
        givenNames:
          - L
      - type: Person
        familyNames:
          - Lianidou
        givenNames:
          - E
      - type: Person
        familyNames:
          - Krylov
        givenNames:
          - SN
    datePublished: '2015'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Am J Pathol
        volumeNumber: 185
      issueNumber: 3
    pageEnd: 703
    pageStart: 693
    title: >-
      Low expression of miR-126 is a prognostic marker for metastatic clear cell
      renal cell carcinoma
  - type: Article
    id: pone-0229075-ref032
    authors:
      - type: Person
        familyNames:
          - Chen
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Gorski
        givenNames:
          - DH
    datePublished: '2008'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Blood
        volumeNumber: 111
      issueNumber: 3
    pageEnd: 26
    pageStart: 1217
    title: >-
      Regulation of angiogenesis through a microRNA (miR-130a) that
      down-regulates antiangiogenic homeobox genes GAX and HOXA5
  - type: Article
    id: pone-0229075-ref033
    authors:
      - type: Person
        familyNames:
          - Bex
        givenNames:
          - A
    datePublished: '2017'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        isPartOf:
          type: Periodical
          name: Ann Oncol
        volumeNumber: 28
      issueNumber: 4
    pageEnd: 4
    pageStart: 682
    title: >-
      Adjuvant sunitinib in renal cell carcinoma: from evidence to
      recommendation
title: >-
  miRNA profiling in renal carcinoma suggest the existence of a group of
  pro-angionenic tumors in localized clear cell renal carcinoma
meta:
  authorNotes:
    - >-
      JAFV, EE and AG-P are shareholders in Biomedica Molecular Medicine SL.
      LT-F, GP-V, AZ-M and EL-C are employees of Biomedica Molecular Medicine
      SL. GDV received personal fees from BMS; Roche, Novartis, Pfizer, MSD;
      Bayer, Astellas, Ipsen, Janssen, and SEOM and reports grants from Roche,
      Ipsen, and Pfizer. This does not alter our adherence to PLOS ONE policies
      on sharing data and materials.
---

# Introduction

Renal carcinoma (RC) is the sixth most common cancer in men and the eight in women, with 73,820 estimated new cases and 14,770 estimated deaths in the United States in 2019 \[@pone-0229075-ref001]. Two thirds of patients have localized disease and an additional 16% have locoregional disease (stage III) at diagnosis. A significant proportion of all these patients (up to 40% in stage III) will eventually relapse \[@pone-0229075-ref002, @pone-0229075-ref003].

Antiangiogenic multi-kinase inhibitors have demonstrated significant efficacy in the metastatic setting, but have not fulfilled expectations in the adjuvant setting. Sorafenib (SORCE trial), pazopanib (PROTECT trial) and axitinib (ATLAS trial) failed to improve disease-free survival when compared with placebo, whereas sunitinib improved disease-free survival but did not impact in overall survival (STRAC trial) \[@pone-0229075-ref004–@pone-0229075-ref007]. As a consequence, sunitinib has been approved for adjuvant therapy by the Food and Drug Administration, but not by the European Medicines Agency and observation remains the standard of care after resection.

The current classical classification of renal carcinoma refers to subtypes that have been named on the basis of predominant cytoplasmic or architectural features, anatomic location, correlation with a specific disease background, as well as molecular alterations or familial syndromes \[@pone-0229075-ref008]. The Cancer Genome Atlas has made considerable efforts to molecularly characterized different neoplasms, amongst them, renal carcinoma, establishing molecular characteristics of the different histological renal subtypes \[@pone-0229075-ref009, @pone-0229075-ref010]. So far, this information has not contributed to improve the personalized treatment for patients with renal cell carcinoma.

Molecular markers different from gene expression could improve our understanding of this disease. MicroRNAs are small RNA sequences which regulate different cellular processes, such as cellular proliferation, apoptosis or stem cell differentiation \[@pone-0229075-ref011]. They are good molecular biomarkers or even therapeutic targets, especially in clinical paraffin samples, because of their stability. \[@pone-0229075-ref012]. For these reasons, miRNAs may have acquired importance as biomarkers in cancer. There are several studies in which microRNAs have been related to chemotherapy resistant or to cancer prognosis and detection \[@pone-0229075-ref013, @pone-0229075-ref014].

The aim of this study is to determine miRNA profiles which allow us to characterize RC subtypes. Interestingly, we identified two groups of clear cell renal carcinoma (ccRCC) tumors, one of them with an overexpression of pro-angiogenic microRNAs.

# Material and methods

## Samples

One hundred and sixty-four patients diagnosed with localized RC were recruited for this study. An observational study was carried out, where all radical and partial nephrectomies performed at Hospital Universitario 12 de Octubre in Madrid between 1999 and 2008 were included. Written informed consent was obtained from all patients. The protocol was approved by the Ethical Committee of Hospital Universitario 12 de Octubre. The evolution of these patients was obtained from clinical records.

## miRNA isolation and quantification

396 miRNAs were measured from 164 renal formalin-fixed paraffin-embedded (FFPE) tumor samples. microRNA extraction and sample processing were done as previously described \[@pone-0229075-ref015]. Briefly, selected FFPE tumor specimens were cut into serial sections with a thickness of 10 μm. Total RNA was then isolated using the miRNEasy Kit (Quiagen). Purified RNA quality control for quantity and purity was assessed using an ND-1000 NanoDrop spectrophotometer (Thermo Fisher Scientific).

## MicroRNA arrays

MicroRNA arrays experiments were done as previously described \[@pone-0229075-ref016]. Briefly, samples were hybridized to Human miRNA Microarray Release 14.0, 8x15K (Agilent Technologies). MicroRNA Labeling Kit (Agilent Technologies) was used to label RNA. 100 ng of total RNA were dephosphorylated and Cyanine 3-pCp molecule was ligated to the 3´ end of each RNA molecule by using T4 RNA ligase. One hundred ng of Cy3 labeled RNA were hybridized for 20 hours at 55°C in a hybridization oven (G2545A, Agilent) set to 20 rpm in a final concentration of 1X GE Blocking Agent and 1X Hi-RPM Hybridization Buffer, according to manufacturer's instructions (miRNA Microarray System Protocol, Agilent Technologies). Arrays were washed according to manufacturer's instructions (miRNA Microarray System Protocol, Agilent Technologies), dried out using a centrifuge at 1000 rpm for 2 min and scanned at 5μm resolution on an Agilent DNA Microarray Scanner (G2565BA, Agilent Technologies) equipped with extended dynamic range (XDR) software. Images provided by the scanner were analyzed using Agilent´s software Feature Extraction version 10.7.3.1. Data were quantile normalized as previously described \[@pone-0229075-ref017].

Only miRNAs with an average intensity over the 20th percentile of the overall intensities and a detectable signal in at least 10 percent of the hybridized samples considered for further analysis. Batch effect was corrected using ComBat software \[@pone-0229075-ref018]. Data is available in Gene Expression Omnibus Database under the identifier GSE144082.

## Consensus cluster

Consensus cluster using R v3.2.5 and _ConsensusClusterPlus_ package was performed to establish subgroups \[@pone-0229075-ref019]. Consensus cluster allows the determination of the optimum number of groups based on the similarity between expression profiles. Then, differential miRNAs expression patterns among groups was analyzed by Significance Analysis of Microarrays (SAM) with MeV 4.9 \[@pone-0229075-ref020]. SAM performed a t-test correcting over permutations of the number of samples \[@pone-0229075-ref021].

Targets of these differential miRNAs were searched in miRwalk database \[@pone-0229075-ref022]. This information was used to perform a gene ontology analysis and to establish relationship with biological functions. Gene ontology analyses were done using Enrichr webtool developed by Ma’ayan lab \[@pone-0229075-ref023].

## Statistical analyses

Statistical analyses were done using GraphPad Prism v6. All p-values were two-sided and considered statistically significant under 0.05. For survival analyses between the two groups defined in ccRCC patients, a log-rank test was used to compare the two obtained curves. Additionally, contingency analyses (Chi-squared tests) were used to establish the independence between clinical data and the new ccRCC classification. For comparisons of angiogenic microRNA expression between the two ccRCC groups, non-parametric Mann- Whitney tests were used.

# Results

## Patient cohort

164 renal tumor samples were studied. One hundred of these samples corresponded to clear-cell carcinomas (ccRCC), 16 to papillary tumors, and 21 chromophobe tumors. Subtype information was not available for 27 tumors. Of these 164 samples, clinical data were available for 142 patients. Twenty-three percent of the patients suffered a relapse and the median of follow-up was 54 months. The median overall survival was 57 months. Clinical characteristics of these patients were summarized in [Table 1](#pone-0229075-t001).

|                        | Number of patients | Percentage |
| ---------------------- | ------------------ | ---------- |
| **Number of patients** | 142                | 100%       |
| **Age (median)**       | 34–83 (66)         |            |
| **Gender**             |                    |            |
| **Male**               | 85                 | 60%        |
| **Female**             | 57                 | 40%        |
| **ECOG-Karnofsky**     |                    |            |
| 90–100                 | 106                | 74.6%      |
| 70–90                  | 31                 | 21.8%      |
| 50–70                  | 4                  | 2.9%       |
| 30–40                  | 1                  | 0.7%       |
| **Furhman grade**      |                    |            |
| 0                      | 1                  | 0.7%       |
| 1                      | 7                  | 5%         |
| 2                      | 74                 | 52%        |
| 3                      | 38                 | 27%        |
| 4                      | 7                  | 5%         |
| Unknown                | 15                 | 10.3%      |
| **Tumor size**         |                    |            |
| **T1**                 | 97                 | 69%        |
| **T2**                 | 19                 | 13%        |
| **T3**                 | 26                 | 18%        |
| **Nodal stage**        |                    |            |
| **N0**                 | 131                | 92.3%      |
| **N1**                 | 5                  | 3.5%       |
| **N2**                 | 6                  | 4.2%       |
| **Nephrectomy**        |                    |            |
| **Radical**            | 116                | 82%        |
| **Partial**            | 23                 | 16%        |
| **Unknown**            | 3                  | 2%         |

## Characterization of differences between histological subtypes

A SAM was done to characterize different miRNA expression patterns between histological groups. It was not possible to find differential miRNAs between papillary and the two other histological subtypes. SAM showed that chromophobe tumors are a very homogeneous molecular group with a higher expression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p ([Fig 1](#pone-0229075-g001)).

figure: Fig 1
:::
![](<>){inline linkType=simple}

### SAM of chromophobe subtype against the rest of tumors.

ccRCC = Clear cell renal carcinoma.
:::

On the other hand, ccRCC tumors were split into two different groups in the SAM graph, suggesting the existence of two molecular groups in ccRCC according the miRNA expression ([Fig 2](#pone-0229075-g002)).

figure: Fig 2
:::
![](<>){inline linkType=simple}

### SAM of ccRCC tumors against the rest of them.

ccRCC = Clear cell renal carcinoma.
:::

## ccRCC groups’ characterization

With the aim of establishing these possible subgroups in ccRCC, a consensus cluster was done. Consensus cluster grouped patients by the similarity in their expression patterns and it allows the definition of the optimum number of groups, showing that two different molecular patient groups existed in ccRCC: ccRCC1 (44 patients) and ccRCC2 (56 patients) ([Fig 3](#pone-0229075-g003)).

figure: Fig 3
:::
![](<>){inline linkType=simple}

### 

**A.** Delta graph suggested two groups as the optimum number of groups in these subtype. **B.** Tracking plot showed different sample classifications making different number of groups.
:::

Contingency analyses showed that this new ccRCC classification was independent from clinical data, such as tumor size or nodal status; i.e, there are no differences in tumor size or nodal status between these two groups (p = 0.55 and p = 0.39 respectively). However, ccRCC2 tumors had a lower Furhman grade than ccRCC1 tumors (p = 0.04).

Moreover, a SAM established 136 differentially expressed miRNAs between these two groups ([Fig 4](#pone-0229075-g004)).

figure: Fig 4
:::
![](<>){inline linkType=simple}

### SAM between two ccRCC identified groups.
:::

Experimentally validated targets of these 136 miRNAs were determined using miRwalk database, and a gene ontology analysis of these genes was performed afterwards. This analysis showed that these genes were mainly related with focal adhesion, transcription, apoptosis and angiogenesis processes ([Fig 5](#pone-0229075-g005)).

figure: Fig 5
:::
![](<>){inline linkType=simple}

### Gene ontology of gene targets of the 136 differential miRNAs.
:::

Additionally, the two subgroups of ccRCC were associated with a different survival, although not statistically significant ([Fig 6](#pone-0229075-g006)).

figure: Fig 6
:::
![](<>){inline linkType=simple}

### Survival curves of the two ccRCC groups defined by Consensus cluster.

**A.** Distant-relapse free survival curves of the two ccRCC groups. **B.** Overall survival curves of the two ccRCC groups.
:::

### New ccRCC groups had differential expression of miRNAs involved in angiogenesis

Interestingly, the two ccRCC subgroups presented differences in expression of some miRNAs previously associated with angiogenesis. In general, ccRCC2 had more expression of miR185, miR126 and miR130a, all of them proangiogenic miRNAs ([Fig 7](#pone-0229075-g007)).

figure: Fig 7
:::
![](<>){inline linkType=simple}

#### miRNAs related with angiogenesis differentialy expressed between two ccRCC groups.
:::

# Discussion

Renal-cell carcinoma comprises several histological subgroups \[@pone-0229075-ref008]. The Cancer Genome Atlas analyzed these histological subtypes and characterized molecular differences between them \[@pone-0229075-ref009, @pone-0229075-ref010]. However, all these advances have not been translated into clinical applications yet. For this reason, further insight into the molecular biology of these tumors is still needed.

There are previous classifications of renal histological subtypes based on miRNA signatures, although a reduce number of miRNAs were used in these analyses \[@pone-0229075-ref024–@pone-0229075-ref026]. In this study, 396 miRNAs were analyzed in 164 RC FFPE samples by microRNA arrays. The main advantage of the measurement of miRNAs is that they are more stable than longer RNAs or DNA in paraffin samples \[@pone-0229075-ref012].

SAM showed differences at the miRNA expression level in chromophobe and ccRCC, but no in papillary tumors. The fact that it was not possible to define differential miRNAs in the papillary subgroup could be due to the reduced number of this type of tumors in our cohort and the intrinsic heterogeneity of this group.

miR10-a, miR222, and miR221 have been previously described as overexpressed in chromophobe subtype, what agrees with our results \[@pone-0229075-ref025, @pone-0229075-ref026].

Regarding ccRCC tumors, differential expression pattern analysis suggested the existence of two different groups inside this histological subtype. This was confirmed by Consensus Cluster, which defined two groups with different expression in miRNAs whose established targets are related to angiogenesis, apoptosis, transcription and focal adhesion.

Interestingly, three of the miRNAs (miR185, miR126, and miR130a) differentially expressed between our two ccRCC groups have been previously related with pro-angiogenesis processes.

Expression levels of miR185 have been correlated with tumor size, Fuhrman grade, and TNM staging. The overexpression of this miRNA inhibited proliferation and induced apoptosis \[@pone-0229075-ref027]. Moreover, elevated miR185 levels were associated with high vascular endothelial growth factor receptor 2 (VEGFR) expression and therefore a pro-angiogenic activity in ccRCC \[@pone-0229075-ref028].

On the other hand, miR126 inhibits the expression of vascular cell adhesion molecule 1 (VCAM1) implicated in leukocyte adherence to endothelial cells \[@pone-0229075-ref029]. This miRNA has a pro-angiogenic function \[@pone-0229075-ref030]. It is downregulated in metastatic ccRCC versus primary tumors. Its overexpression is negatively correlated with tumor size and is associated with longer distant relapse-free survival and overall survival. miR126 overexpression is also related with a reduction in cellular proliferation \[@pone-0229075-ref031]. According to these facts, miR126 was underexpressed in our ccRCC1 group which had a worst prognosis.

miR130a were identified as proangiogenic miRNA due to its inhibitory effect in the anti-angiogenic homeobox GAX and HoxA5 \[@pone-0229075-ref032]. A relationship between this miRNA and renal carcinoma had not been previously described.

Considering the controversial efficacy of antiangiogenic drugs in the adjuvant setting of renal-cell carcinoma \[@pone-0229075-ref033], defining a proangiogenic group may be important to select patients more likely to benefit from these treatments. In the future, a class predictor could be developed to define this pro-angiogenic group. Such a predictor should be validated in an independent cohort.

In this work, we have characterized differences between RC histological subtypes using miRNAs and have defined two ccRCC groups with different expression of pro-angiogenic miRNAs. Differences between subtypes could be used as therapeutic targets or as a method to select patients for personalized treatments in the future.

# Supporting information

